skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

72 Total results for product and free and sample content found

Pink Sheet

Act Quickly On Converted EU Product Approvals GB Firms Urged

By Ian Schofield 23 Nov 2020

Act Quickly On Converted EU Product Approvals, GB Firms Urged

The UK medicines regulator has written to pharmaceutical companies outlining the actions they need to take regarding products with a centralized EU approval that will be converted to Great Britain marketing authorizations next year. 

Topic Pharma-Brexit Brexit Approvals

Medtech Insight

QUOTED. 24 January 2020. Megan McSeveney.

30 Jan 2020

Quoted_24_January_2020

The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.

Topic Approvals Coronavirus FDA

Scrip

Podcast: Significant Approvals, Diabetes and NASH In India, Japan M&A

By Brian Yang 18 Dec 2019

Podcast_Significant_Approvals_Diabetes_And_NASH

Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at some of the most significant regional pharma stories of the past few weeks.

Topic Approvals Business Strategies

Datamonitor Healthcare

Webinar: Outlook for NASH Therapies and Market Dynamics

By Joseph Haas 04 Nov 2019

Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

Topic Cell & Gene Therapy Drug Development Landscape Approvals

Biomedtracker

Q3 2019 Catalyst Roundup

16 Oct 2019

Q3 2019 Catalyst Roundup

What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

Topic Approvals Drug Review FDA

Pink Sheet

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

16 Oct 2019

Pink Sheet Sample Article Pack: The Hottest Topics in Pharma Regulatory Compliance

When you look at newly approved drugs, the latest product reviews and the decisions made during the process, you can gain critical insights to inform your own strategic decisions. That’s what Pink Sheet delivers, and now you can try it for free.

Topic Approvals Drug Development Landscape

Datamonitor Healthcare

Providing Coverage of the Commercial Topics in Q3

10 Oct 2019

Providing Coverage of the Commercial Topics in Q3

The Commercial Solutions Strategy Suite from Informa Pharma Intelligence unites the power of vital tools to bring you actionable data, penetrating analysis, and a crucial industry view covering a variety of critical market aspects, allowing you to accurately Forecast, Analyze and Benchmark, and Understand the mark landscape.   

Topic Approvals Drug Development Landscape

Biomedtracker, Datamonitor Healthcare

Key potential drug launches 2020

27 Sep 2019

Key potential drug launches 2020

Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

Topic Approvals Drug Review Drug Development Landscape

Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Approvals

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: